3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol in 1 studies
| Studies (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Trials (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Recent Studies (post-2010) (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) |
|---|---|---|---|---|---|
| 330 | 40 | 33 | 90 | 1 | 2 |
| Protein | Taxonomy | 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide (IC50) | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.83 | |
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | 6.43 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.83 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.8267 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.91 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.8267 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 1.5 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 1.5 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 1.5 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.8267 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 2.431 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 6.9225 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.06 | |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | 0.073 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreas, J; Benkert, O; Eissner, D; Gründer, G; Heydari, N; Müller, MJ; Nickel, O; Schlegel, S; Schlösser, R; Wetzel, H | 1 |
1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol
| Article | Year |
|---|---|
Occupancy of striatal D(2)-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzamides; Blood-Brain Barrier; Corpus Striatum; Female; Humans; Male; Middle Aged; Oxazoles; Piperidines; Pyrimidines; Pyrrolidines; Receptors, Dopamine D2; Receptors, sigma; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1999 |